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Antagonism of Quinidine's Electrophysiologic Effects by Epinephrine
in Patients With Ventricular Tachycardia
FRED MORADY, MD, FACC, WILLIAM H . KOU, MD, ALAN H. KADISH, MD,
STEVEN D. NELSON, MD, LAURI K. TOIVONEN, MD, JEFFREY A . KUSHNER, MD,
STEPHEN SCHMALTZ, MPH, MICHAEL or BUITLEIR, MD
Ann Arbor, Michigan
The purpose of this study was to determine whether phar-
macologically induced elevations In the plasma epinephrine
concentration within reported physiologic limits oiler the
response t quinidine during dedropbarmacologic testing .
Twenty-one patients with coronary artery disease and a
history of unimorphle ventricular taehyeordla were found
to have inducible sustained unimorphie ventricular tachy-
cardia that was suppressed by treatment with oral quint
.
dine gluconate. Epinepbrine was Then infused at a rate of
either 25 or 50 ng/kg per min and testing was repeated .
These infusion rates of epinephrine were previously dem
.
contrasted to result in elevations of the plasma epinephrine
concentration In the range of concentrations that occur
during a variety of stresses .
Quinidlne significantly lengthened the ventricular re-
fractory periods and the QRS duration at a ventricular
pacing cycle length of 350 ots, which was used as an Index
of intraventricular conduction . Epinephrine partially or
completely reversed the effects of quinidine on ventricular
refractory periods, but had no effect on QRS duration .
During electropharmacolegic testing of quinidine, no Yon .
Doses of epin_phrine that result in plasma epinephrine
concentrations within the range of those that occur physio-
logically have been demonstrated to shorten ventricular
refractoriness and, in some patients, to facilitate the induc-
tion of ventricular tachycardia (1). These effects are opposite
to those of quinidine, which lengthens ventricular refracto-
riness and which may suppress the induction of ventricular
tachycardia (2). 'therefore, it is possible that physiologic
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Irlcular mehyeardia was inducible in 12 patients, and only
namustalned ventricular tachycardia, 8 to 48 beats In
duration, was Inducible in 9 patients . Retesting during
infusion of epinephrine demonstrated Inducible sustained
unimorphic ventricular tachycardia in 2 of the 12 patients
in whom quinidine had completely suppressed the Induction
of ventricular tachycardia and In 8 of the 9 patients In
when only nonsustained ventricular tachycardia had been
Inducible during testing of quinidine .
In conclusion, physiologic elevations in the plasma epb
nephrine concentration may reverse quinidine-induced pro-
longation of ventricular refractoriness but not intraventri-
cular conduction. Epinephrine may facilitate the Induction
of sustained ventricular tachycardia In patients in whom
quinidine has suppressed this arrhythmia, Patients In
whom nunsuslained ventricular tachycardia is inducible
during olectruphormecolegic testing may be particularly
susceptible to antagonism by epinephrine of quinldine's
therapeutic effects .
(J Am Cog Cordial 1988;12:388-94)
increases in the plasma epinephrine concentration might
antagonize the therapeutic effects of quinidine . However,
the interactions between the effects of epinephrine and
quinidine to date have not been reported . The purpose of this
study was to determine whether the therapeutic effects of
quinidine in patients who have ventricular tachycardia are
reversed by physiologic plasma concentrations of epineph-
rine induced by intravenous administration of this agent .
Methods
Patients studied. The subjects of this study were 21
consecutive patients who 1) underwent an electrophysiolo-
gic test because of to history of sustained unimorphic ventri-
cular tachycardia, 2) had sustained unimorphic ventricular
tachycardia inducible by programmed stimulation, and 3) no
0735 .
l897158157 .50
tACC Val. 12, Na . 2
Augur 1188188-94
longer had inducible sustained unimorphic ventricular tachy-
cardia after treatment with oral quinidine . There were 20
men and I woman, and their mean age (VSD) was 67 *- I I
years . All 21 patients had coronary artery disease and 16 had
a history of myocardial ipfarction . Their mean left ventricu-
lar ejection fraction was 0.35 *_ 0.1L
Baseline electrophysiolokicstudy, Baseline elecnophysio-
logic studies were performed with patients in the fasting,
unsedated state after they had given informed consent and at
least five half-lives after disco,ttinuation of all antiarrhythmic
drugs and beta-adrenergic blocking agents
. The study proto-
col was approved by the Humae Research Committee at the
University of Michigan
. Quadripolar electrode catheters
were inserted through a femoral vein and positioned against
the right ventricular apex, the right ventricular outflow tract
or septum and across the tricuspid valve for recording the
His bundle electrogram. A short 1F cannula was inserted
into a femoral artery for measuring arterial pressure and for
drawing blood samples to measure the plasma quinidine
concentration, Leads V„ 1, and III, th r- intracardiac electro-
grams and the arterial pressure tracing were recorded on a
Siemens-Elema Mingogaf 7 recorder al, paper speed or 100
to 200 mm/s
. Programmed stimulation was performed with a
programmable stimulator (Bloom Associates) ; the stimuli
were twice the diastolic threshold and 2 ms in duration .
The variables measured included the sinus cycle length
and mean arterial pressure . QRS duration at a ventricular
pacing cycle length of 350 ms was used as an index of
intravenlricular conduction (3). Because the effect of qui-
nidine on conduction are rate dependent (4), a pacing cycle
length of 350 ms was used to maximize the effects of this
agent on QRS duration . The functional and effective refrac-
tory periods were measured at the right ventricular apex
using eight beat drive trains at cycle lengths of 600, 500 and
410 ms, with a 4 s pause between trains . The refractory
periods were determined using 5 ms decrements in the
coupling interval of the ventricular extrastimulus .
Programmed ventricular stimulation was performed with
one and two extrastirPUli at the right ventricular apex, then
at the second right ventricular site using basic drive cycle
lengths of 600 and 400 ms and trains of eight basic drive
beats. If sustained ventricular tachycardia was not induced .
triple extrastimuli were introduced at the apex. then St the
second right ventricular site
. Ventricular tachycardia was
defined as sustained if it was >30 s in duration or required
direct current countershock to terminate
; it was defined as
nonsustained if it was idx bears to 30 s in duration . The
induction of sustained ccntricular tachycardia was found to
be reproducible in all patients who did not require direct
current countershock for termination of ventricular tachy-
cardia . Reproducibility was not assessed in those patients
who required direct current countershock to terminate the
tachycardia.
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Drug testing with quinidine . After the baseline elec-
trophysiologic test, treatment with quinidine gluconate was
initialed . The dose was either 486 or 648 mg every 8 h .
Electropharmacologic testing was performed after 2 days of
therapy during the last 2 h of the dosing interval . The
variables measured in the baseline electrophysiologic test
were measured again . Programmed ventricular stimulation
was then performed with the same stimulation protocol used
in the baseline electrophysiologic test . The Pad point of the
stimulation protocol was the induction of sustained ventri-
cular tachycardia or completion of the entire stimulation
protocol at both right ventricular sites with one, two and
three extrastimuli . In accord with the selection criteria for
this study, none of the patients had inducible sustained
ventricular tachycardia during electropharmaeologie testing
with quinidine.
Epinephrine Infusion, After the effects of quinidine were
determined . epinephrine was infused at a rate of 25 nglkg per
min in 9 patients and 50 ng/kg per min in 12 . These infusion
rates were used because they have previously been demon-
strated to result in a mild to moderate elevation of the plasma
epinephrine concentration (1,5) and their electrophysiologic
effects have been characterized in detail (I) . Previous studies
have demonstrated that a steady state concentration is
achieved after 10 min of infusion (6,7). Therefore, the
epinephrine infusion was continued for 14 min before testing
to assure that a constant plasma epinephrine concentration
was present.
The sinus cycle length, mean arterial pressure, QRS
duration at a ventricular pacing cycle length of 350 ms and
the right ventricular refractory periods were measured dur-
ing the infusion of epinephrine. Programmed ventricular
stimulation then was repeated with the same stimulation
protocol described. As before, the end point of the stimula-
tion protocol was the induction of sustained ventricular
tachycardia or completion of the entire stimulation program .
The plasma quinidine concentration was determined im-
mediately before the start of the epinephrine infusion and
again after completion of testing of the effects of epineph-
rine . The mean plasma quinidine concentrations at these
times were 3.1 ± 1 .1 and 3 .0 ± 1.1 mg/liter, respectively .
The time interval required to infuse epinephrine and test its
effects ranged from 25 to 35 min .
Effects of epinephrine in the absence of quinidine . The
effects of 25 nglkg per min of epinephrine on induced
ventricular tachycardia in the absence of quinidine were
determined in six patients who had hemodynamically toler-
ated sustained ventricular tachycardia in the baseline state .
This group of patients consisted of three patients in whom
the effects of epinephrine also were determined subse-
quently in the presence of quinidine, and an additional three
patients who had inducible sustained ventricular tachycardia
daring treatment with quinidine and therefore did not un-
dergo retesting with epinephrine . The effects of 50 ng/kg per
390
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Table 1
. Effects of 25 ng/kg per min of Epinephrine in Sir
Patients in the Absence of Quinidine
-Mean t SD: +during ventricular pacing. cycle length 350 ms . CL = cycle
length
: DCL = drive cycle length ; MAP = mean uncriel pressure: VERY=
effective refractory period: VFRP = runctionul refractory period : VT =
ventricular tachycardia .
min of epinephrine on induced ventricular tachycardia were
not determined in the absence of quinidine to avoid inducing
hemodynamically unstable ventricular tachycardia .
Statistical analysis
. The effects of epinephrine in the
absence of quinidine were analyzed using a paired f test . The
effects on each variable of quinidine and quinidine plus
epinephrine, as well as the effects of the two doses of
epinephrine, were analyzed using a repeated measure anal-
ysis of variance (8). Multiple comparisons were performed
using Fisher's least significant difference procedure (8) . The
sinus cycle length was <600 ms in 4 of the 12 patients who
received the 50 ng/kg per min infusion of epinephrine ;
therefore, refractory periods could not be measured at a
basic drive cycle length of 600 ms in these four patients. A
mixed model analysis of variance was used to analyze the
data for the variables that had missing data (9). A p value
<0 .05 was considered significant .
Table 2. Effects of Quinidine and Quinidine Plus 25 ng/kg per min of Epinephrine in Nine Patients
Results
Effects of epinephrine In the absence of quinidine (Table 1).
The effects of 25 ng/kg per min of epinephrine in the absence
of quinidine in six patients arc described in Table I . The
mean dose of epinephrine was 2.0 ± 0.4 ytg/min . Epinephrine
tesulted in a significant decrease in sinus cycle length and
refractory periods but had no effect on QRS duration at a
ventricular pacing cycle length
of 350
ms
. In each patient the
unimorphic ventricular tachycardia induced in the baseline
state and during the epinephrine infusion had the same
configuration. 'The mean cycle length of the ventricular
tachycardia was significantly shortened by epinephrine . In
five patients whose baseline ventricular tachycardia cycle
length was 320 to 400 ms . epinephrine shortened it by 30 to
80 ms
. In one patient whose baseline ventricular tachycardia
cycle length was 230 ms, the cycle length was not affected by
epinephrine . Either two or three extrastimuli were required
to induce ventricular tachycardia in the baseline state.
During infusion of epinephrine, the number of extrastimuli
required to induce ventricular tachycardia decreased by one
in three patients and remained unchanged in the others
.
Effects of 25 nglkg per min of epinephrine In the presence
of quinidine (Tables 2 and 3). The daily dose of quinidine
gluconate in each of these nine patients was 1,944 mg and the
mean dose of epinephrine was
2 .0 ± 0.4 )4g/min . The
electrophysiologic effects of quinidine and quinidine plus
epinephrine are described in Table
2. Quinidine resulted in a
significant prolongation of the refractory periods and QRS
duration . Epinephrine partially reversed the effects of quini-
dine on the refractory periods but had no effect on the QRS
duration .
In accord with the selection criteria fn this study, quini-
dine suppressed the induction of sustained ventricular tachy-
cardia in every patient . No ventricular lachycardia was
inducible in five patients and nonsustained ventricular tachy-
cardia 10 to 48 beats in duration was inducible in four
JACC Vul . 12.
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'Mean t SD:'du6ng venuricular pacing. cycle length 350 ms . a = bacaline ; E = epinephrine : NS = not s,grificanl : Q = quinidine; other aphrevialions :u
in 7 able I .
p Values
R Q Q+E Qv .B Q+Ev,Q 2 .I.Ver,usB
Sinus CL Ims) 751 *_ 118" 835 t 92 741 87 0.05
.0115
NS
MAP (tort) 89 m 5 94 x 9 X5 t
9
NS NS
NS
VERP (msl
DCL648en
259! 10 296 t 16 279 v 17 <0.0ul 10,001 <0.101
DCL 5011 ee 247 t 12 2822
19 265
t 19 <0.1091 <0.01 <11.01
DCL 400 nu
242 0 12 272 * 20 25 4
3
16
<0
.0/I
<11
.001
<11.05
VFRP Ims)
DCL 61)0 ms 288 m 8
3'5 _ 211
301 -
15 <6.101 <1001 x1.01
DCL 50D ms
277 0
8
109 _ 22 288 *_ 17 <0911 <11.011 <I1.05
DCL 400 ms 272 - 11 298 x 19 279 x 17 <6 .1011 0,001 INS
QRSlmsl' 170! 1 8 196-19 194922 10 .001 NS <0.1X11
Baseline Epinephrine
P Value
Sinus CL
Ims) 735 ` 106• 683 s 113 .0 .05
MAP (tort)
93 x I I 89 m Ill NS
VERP(ms)
DCL600ms 259-2
250_7 .0.01
DCL SIX) re 251 *_ 238 ± 6 0.01
DCL 400 ms 278 . 3 228
t
3 .11.01
VFRP1me)
DCL 600 ms 288 - 8 274 ± 13 <D.01
DCL slxl ms 274 .• 9 264 -_ I I <0.01
DCL 400 ms 265 ± 9 255 s 10 <0.01
QRS (ms)}
166 s 6 168 a 6 NS
VT CL (ms) 324 *_ 55 287 t 31 <0.05
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Table 3. Effects of Quinidine and Quinidinc Plus 25 ng/kg per min of Epinephrine on Induced Ventricular Tachycurdia in Nine Patients
'13--fire culnr,achycarJiue'mzuslaincdineve,yp' •' oenl .C1 .-,'dolennm :ES= requiredh,indna -I-u6,lachycordt; :l=inferior
s : LB - lea bundle Stench hloek vmalgnalian : Nomh -- morphology: Ibly - p,,I In pIna.(3 „Imupl:n'
li
m'e yninidine emmenlraliun : RR = light handle Stanch
block canSgurution : S = superior axir, Susl = s;mined .
patients. Among the five patients who did not have inducible
ventricular tachycardia during drug testing with quinidine .
repent stimulation during infusion of 25 ng/kg per min of
epinephrine resulted in the induction
of
nonsustained ven-
tricular tachycardia 16 to 20 beats in duration in two patients
and sustained tachycardia in oar patient (Table 3) . Among
the four patients who had inducible nonsnstained ventricular
tachycardia during drug testing with quinidine
•
all four had
inducihle sustained tachycardia during infusion of 25 ng/kg
per min of epinephrine . The characteristics of the induced
ventricular tnchycordia, the number of cstrastimuti required
to induce it and the plasma quinidine concentrations are
presented in Table 3 .
Effects of 50 ng/kg per min of epinephrine In the presence
of quinidine (Tables 4 and 5) . The mean daily dose of
quinidine glueonnfe in these 12 patients was 1,822 i 220 mg •
and the mean dose of epinephrine was 3
.8 ± 0.6 µg/min
. The
electrophysiologic effects of quinidine and quinidine plus
epinephrine are described in Table 4. Quinidinc resulted in a
significant prolongation of the refractory periods and QRS
Table 4• Effect•
,
of Quinidine and Quinidine Plus 51) ng/kg per loin of Epinephrine in i2 Patients
duration . lipinephrinc partially or completely reversed the
effects of quinidine on the ventricular refractory periods but
had no effect on the QRS duration .
Daring drug testing with quinidine, seven patients had no
inducible ventricular tachycantia . Among these seven pa-
licnls, repeal stimulation during infusion of 50 ng/kg per min
of epinephrine resulted in the induction of nonsustained
ventricular tachycardia 12 to 23 beats in duration in two
patients and sustained tachycardia in one patient (Table 5)
.
Among hoe patients who had inducible nonsustained ventri-
cular tachycardia 8 to 25 beats in duration during drug testing
with quinidine . four of the five had inducible sustained
tachycardia during infusion of epinephrine . The characteris-
tics of the induced ventricular tachycardia, the number of
extrastimuli required to induce it and the plasma quinidine
concentrations are presented in Table 5 .
Changes in the plasma quinidine concentration . Overall.
epinephrine affected the results of programmed ventricular
stimulation in 14 patients treated with quinidine and had no
effect in , patients . The mean change in the plasma quinidine
'Mean a SD : 'during ventricu/: r pacing . cycle length 350 nn . Abbiclioton, . ,in Tuhlcs I and 2 .
If Q Qel(
p Vahres
Uvslt Q+I:vsQ Q+Evst
SmurCLlms) 7M' Ian° nI6 t 154 Ivy 117 NS <0Am <0 .01
MAP 0nrr1 59 - 10 95 ` 10 89 1 11 <0L05 <0 .01 NS
VERPins)
DCL M0 m 751 1 17 289 • 21 Q 11 10 .0111 INS
DUL 510 ns 241 r. 2 1.7 ' 20 249 t 21 <11 .001 <10flf1 NS
DCI .400ass 211115 258117 4, 16 <5.101 <03001 NS
VFRP most
DCL 1000 ms 279 x 13 1111 - 21. No n 20 1011X01 -<1101 <0,01
uCl . 51x4 ms 21,1 ' 15 292 x 17 17,1 ' 211 <0 0)1 <0)9)1 NS
DCL 410 ms 256 ± 16 28I * 16 2262 : . 15 <31,101
<0
.001
NS
QR5 ims11 114 2 16 191 z 16 188 t 16 <0 .011 NS
<Blot
umdinc Qmmdu
. Quinidine and Epinephrine
Pmienl
Darm6n Q
Duration Q
No .
Morph C[
.( .,l No ES Mnrph C1. <nt
Inn
. of heal Nn. 6 . unnailcrl MorDh
CL Ins)
Inn . of beak) No. ES Imgdner)
I RS.S 250 1 - - an
Rat
150)
Stool r
4.h
LR .S 220 1 - - - 'x Poly 2 10 20 2.8
3 lint 310 - - - Rn .1 140 16 3 2 .1
4 LS .S 341) - 11 - 2 .0
- -
11 - 1 .9
5 La .S 220 - - I - - 0 - 2.1
6 RS,S 320 RH 350
1
1 A WS 120 Soot 1 IS
7 00 .5 230 all S 3211
1
4 .1) RO.s loll Soot I 39
8 1.3,S 335 Ln .S 4411 34 R1t.S 2290 Soot 1 17
9 LB ,S 2711 2 RO .S 40) 411 4 .9 RR.1 Ova Snot 4.7
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Table 5 . Elfeclo
of Quinidine and Quinidiuc Plus 50 nglkg per min of Epinephrine on induced Ventricular Tachycardia 4, 12
Patients
'11-one ventricular wchycardia ups sustained m every puliert Abhreviatmns as in fable 3 .
concentration during infusion of epinephrine wits 0.1 ± 0.06
mglliter in the former and 0.1 ± 0 .1 mg/liter in the latter
patients,
Comparison of the effects of the two epinephrine Infusion
rates. In the presence of quinidine . the effects of the 50 ng/
kg per min infusion of epinephrine on The ventricular effec-
tive refractory period al a drive cycle length of 400 ms and on
the functional refractory period at drive cycle lengths of figl,
500 and 400 ms were significantly greater than the effects of
25 ng/kg per min of epinephrine (p < 0.05) . There was a
tendency for the effects of 50 ng/kg per min of epinephrine on
ventricular effective refractory period at drive cycle lengths
of 600 and 500 ms to be greater in magnitude than the effects
of the 25 mg/kg per min infusion (0 .05 < p < 0,1) .
The
proportion of patients who had inducible sustained and
nonsustained ventricular tachycardia during infusion of epi .
nephrine in the presence of quinidine was similar for both
infusion rates
.
Discussion
Antagonism of the effeels or quintdlne by epinephrine. The
results of this study demonstrate that epinephrine may
partially or completely reverse the effects of quinidine on
ventricular refractory period and also may facilitate the
induction of ventricular tachycardia in patients in ss'hom
quinidine has suppressed the induction of sustained ventri-
cular tachycardia
. Plasma epinephrine concentrations were
not measured in this study ; however, the doses of epineph-
rine used have been previously demonstrated (1,5) to result
in plasma eninephdne concentrations similar to those that
occur during a variety of physiologic and pathophy . iologic
states in lnemans . The 25 ng/kg per min epinephrine infusion
results in plasma epinephrine concentrations in the range
that occurs during cigarette smoking (10), public speaking
JACC vet . 12, No . I
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(11) . submaximal exercise (5) . mild hypoglycemia (10) .
den-
tal extraction (121 and surgery (13) . The So ng/kg per min
epinephrine infusion results in plasma epinephrine concen-
trations in the range that occurs during maximal exercise (5),
acute myocardial infarction (14,15), diabetic ketoacidosis
(101 and severe hypoglycemia !10) . Therefore, the elevated
plasma epinephrine Concentrations that occur during expli-
sure to a variety of stresses potentially may antagonize the
therapeutic effects of quinidine in patients in whom quinidine
has been determined to be effective in suppressing sustained
ventricular tachycardia during electropharmacologic testing .
Effects of epinephrine on ventricular refractoriness and
QRS duration . In the absence of quinidine, epinephrine
significantly shortened the ventricular refractory periods but
had no effect on the QRS duration . These findings are in
accord with the results ora prior study of the electrophysio-
logic effects of c, inephrine (I) and are consistent with the
known cellular ePeos of beta-adrenergic stimulation on the
action potential in ventricular myocardium, which include a
shortening of the action potential duration but no ef'ect on
the upstroke velocity (16).
The magnitude of the effects of epinephrine on ventricular
refractory periods in the presence of quinidine was al k'.ast as
great as the magnitude of the effects in the absence of
quinidine, Therefore, quinidine does not appear to attenuate
the shortening in ventricular refractory periods that -curs
in response to epinephrine . As was the case in the baseline
stale, epinephrine had no effect on ORS duration it the
presence of quinidine . To the extent That QRS duration may
be an index of intraventricular conduction, this finding
suggests that epinephrine does not reverse the slowing of
conduction that occurs in response to quinidine .
Effects of epinephrine on the induction of ventricular
tachycardia
. For reasons of patient safety, the affects of
epinephrine on induced ventricular tachycardia in the ah-
Proem
Na
Vaseline•
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sence of quinidine were tested only with the 25 ng/kg per min
dose of epinephrine and only in patients in whore ventricular
tachycardia was tolerated hemodynamically in the baseline
slate
. In five of six patients, epinephrine resulted in a 30 to g0
rev decrease in the ventricular lach-,canlia cycle length and
in three of the six patients, it decreased the number of
extrastimuli required to ^dree ventricular tachycardia .
However, the effects of epinephrine on ventricular mchycar-
dia that is associated with significant hemodynamic compro-
mise remain unknown . It is possible that the epinephrine
infusion would have less effect on ventricular tachycardia
that is associated with severe hypotension and intense
intrinsic adrenergic activation .
the
results of elir'trophamun»lugir testing mill, quini-
dine acre altered sigmfirmrt(v hr epirephrine in 10,4 the Zl
pnticnls io this sruNN . These Ill patrcn(s, who all had
inducible sustained ventricular tachycardia in the baseline
state, were found to have either no nducible or only
nousttstaincd ventricular tachycardia during treatment with
quinidine
. However, infusion of epinephrine in these pa-
tients reversed the response to quinidine so that sustained
ventricular tachycardia was again inducible . Because repeat
programmed stimulation during infusion of epinephrine was
completed within approximately 30 win alter clcctropharnn-
cologie testing with quinidine . because there was only a
minor change in the plasma quinidine concentration during
this time and because the mean change in the plasmm
quinidine concentration was the same whether or not epi-
nephrine altered the results of programmed stimulation, it is
unlikely that the results of programmed ventricular stimula-
tion were affected by changes in the effects of quinidine over
time .
The response to epinephrine n-ass dependenl on the drgi ee
m ninth quinidine :,uppressrd Nor inducripn of rentrioudar
turhyrardia . Arming the 12 patients in whom quinidine
completely suppressed the induction of vcotricular tachycar-
dia, sustained ventricular tachycardia was induced during
infusion of epinephrine in only 2 . In contrast, among the nine
patients in whom nonsustained ventricular tachycardia was
inducible during drug testing with quinidine, the induced
tachycardia became sustained in eight patients during infu-
sion of epinephrine Therefore, physiologic elevations of the
plasma epinephrine concentration may he more likely to
facilitate the induction of sustained ventricular tachycardia
in patients who demonstrate a partial response to quinidine
than in patients in whom quinidine has completely sup-
pressed the induction of ventricular tachycardia .
In some patients, the confrgumtion of the ventricular
tachycardia induced during infusion of epinephrinc differed
from that of the tachycardia induced in me baseline stair or
after treatment with quinidine Because a 12 lead electrocar-
diogram of every spontaneous episode of ventricular tachy .
cardia in each patient was not available . the clinical signifi-
MORAOY FT AL-
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canes of the various configurations of induced unimorphic
ventricular tachycardia cannot he ascertained .
(Arse effeels of epinephrine . The effects of epipcphrine on
the ventricular refractory period in the presence of quinidine
tended to he dose dependent, with the effects of the 50 nglkg
per min infusion generally being greater in ulagu6~ .: ..
the effects of the 25 ng/kg per min infusion . However . the
effects iii epinephrine on the results of programmed ventri-
cular stimulation in the presence of quinidine were similar
for both infusion rates
.
Relevant prior studies. No prior studies have examined
the interaction between aotiarrhythmic drugs and epineph-
rine . However, several prior reports (17-21) have described
antagonism of antiarrhythmic drug effects by beta-
adienergic stimulation with isoproterenol. Wellens ct al . (17)
and Brugada ci al . (ta) reported that isoproterenol shortened
the accessory pathway effective refectory period and facil-
itated the induction of ortholromic tachycardia in patients
with the Welff-Parkinson-White syndrome treated with
amiodarone. In a single patient in whom flecainide com-
pletely blocked ttnterograde conduction through a9 acces-
sory pathway . a 2 pg/min infusion of isoproterenol reversed
the effect of itecainide and allowed conduction through the
accessory pathway at a rate of 260/min (19). In a preliminary
report . Nacearetti et al . (211) determined that a I to 2 pglmin
infusion of isoproterenol partially or completely reversed the
clectrophysiologic effects of encainide on the accessory
pathway and atrioventricular node in 15 patients with the
Woilf-Parkinson-White syndrome . In a preliminary study,
Market el al . Up determined the effects of 30 nglkg per min
of isoproterenol on sustained ventricular tachycardia in fee
patients before and during treatment with procainamide,
quinidine, prupafcnone, mexiletine or lidocaine. Isoprotere-
nol usually was found to antagonize drug-induced slowing of
ventricular tachycardia. The results of these prior studies
suggest that the antagonism of quinidine's effects by
epi-
nephrine
observed in the present study is related to epineph-
rine's hetradrenergic properties .
Limitations of the study . The principal limitation of this
study what it does not establish the clinical significance of
the arrhythmias induced during infusion of epinephrine . The
particular doses of epinephrine used in this study have been
found to result in elevations of the plasma epinephrine
concentration that are within the physiologic range of plasma
epinephrine concentrations that occur during a variety of
dresses in humans
(1,5)
. Therefore, it has been presumed
that the antagonism
of
quinidine's effects by epinephrine in
the clectrophysiology laboratory may he clinically impor-
tant Huwevcr, the present study does not provide long-term
ibllow-up data to establish that this is the case . In this study .
the patios-, in +them epinephrine reversed the therapeutic
efficacy of quinidine were not treated on a long-term basis in
a uniform fashion. Because of this and because of the
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relatively small overall sample size, no meaningful follow-up
data arc available .
Conclusions. Approximately 30%
of
patients who un-
dergo electropharmacologic testing and receive long-term
treatment with an antiarrhythmic drug that has suppressed
the induction of ventricular tachycardia may nevertheless
have a clinical recurrence of ventricular tachycardia over a
follow-up period of
18
months (22) . The results of this study
suggest mat one of the factors responsible for recurrent
ventricular tachycardia during treatment with a drug pre-
dicted to be effective on the basis ei electropharmacologic
testing may be a loss of therapeutic efficacy in the presence
of physiologic elevations in the plasma epinephrine concen-
tration . The ability to induce sustained ventricular tachycar-
din during an infusion of epinephrine in patients in whom
quinidine had suppressed 'he induction of this arrhythmia
suggests that the results of drug testing in the electrophysi-
ology laboratory in the face of adrenergic lone at rest may
not he an accurate indicator of drug efficacy under condi .
tions of stress .
In this study, sustained ventricular tachycardia became
inducible during epinephrine infusion in eight of nine pa-
tients in whom only nonsustained ventricular tachycardia
was inducible during testing of quinidine. Therefore . loss of
therapeutic efficacy in patients treated with quinidine may be
particularly likely to occur during periods of adrenergic
activation when nonsustained ventricular tachycardia has
been used as the end point of drug testing, as has been the
practice in some electrophysiology laboratories (23-25) . The
results of this study suggest that when the response to
quinidine during electropharmacologic testing is complete,
there may be less susceptibility to the antagonistic effects of
epinephrine .
Additional studies will be needed to determine 1) the
clinical relevance
of
electropharmacologic testing during
epinephrine infusion, 2) the interaction between epinephrine
and antiarrhythmic drugs other than quinidine, and 3) the
possible value
of beta-adrenergic blocking agent to prevent
epinephrine-induced therapeutic inefficacy ofantiarrhythmi.
drugs .
We are grateful to Beverly Bestir, Joan Bergeron and Linda Abbott far their
technical assistance, and to Lisa Huckharih for secretarial assistance .
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